You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Medtronic
Express Scripts
Harvard Business School
Baxter

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Sirukumab


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Sirukumab?

Sirukumab is an investigational drug.

There have been 12 clinical trials for Sirukumab. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Giant Cell Arteritis. The leading clinical trial sponsors are GlaxoSmithKline, Janssen Research & Development, LLC, and Janssen Pharmaceutica N.V., Belgium.

There are six US patents protecting this investigational drug and forty-five international patents.

Recent Clinical Trials for Sirukumab
TitleSponsorPhase
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19Janssen Pharmaceutica N.V., BelgiumPhase 2
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia RheumaticaGlaxoSmithKlinePhase 3
A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled AsthmaGlaxoSmithKlinePhase 2

See all Sirukumab clinical trials

Clinical Trial Summary for Sirukumab

Top disease conditions for Sirukumab
Top clinical trial sponsors for Sirukumab

See all Sirukumab clinical trials

US Patents for Sirukumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sirukumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Sirukumab   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
Sirukumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
Sirukumab   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
Sirukumab   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Sirukumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sirukumab

Drugname Country Document Number Estimated Expiration Related US Patent
Sirukumab Australia 2013220749 2032-02-15   Start Trial
Sirukumab Brazil 112014019627 2032-02-15   Start Trial
Sirukumab Canada 2862476 2032-02-15   Start Trial
Sirukumab China 104114705 2032-02-15   Start Trial
Sirukumab China 108570468 2032-02-15   Start Trial
Sirukumab European Patent Office 2814963 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Moodys
Johnson and Johnson
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.